Special Issue "Peripheral Diabetic Neuropathy: Symptoms, Causes and Treatment"
Deadline for manuscript submissions: closed (14 October 2022) | Viewed by 12350
Interests: endocrinology; neurobiology; obesity; diabetes; iron; adipose tissue
Interests: neurobiology; peripheral neuropathy; obesity; diabetes; inflammation
Peripheral diabetic neuropathy (PDN) is a common complication of diabetes mellitus, which leads to structural and functional changes of peripheral nerve fibers. PDN has been recognized as a progressive disease which causes sensitive, motor, or autonomic functional changes to nearly 60 percent of patients with diabetes. However, while clinical examination may identify early signs of neuropathy without symptoms, to date, there is no causal therapy for PDN. The approach is therefore preventive or symptomatic, such as a drug treatment of hyperglycemia and neurological symptoms. Various pathogenic pathways involved in peripheral nerves degeneration have been proposed: i) myoinositol mechanism: hyperglycemia-induced sorbitol accumulation in nerve cells and intracellular myoinositol decrease, ii) oxidative stress, iii) non-enzymatic glycosylation (advances glycosylated end-products—AGE), iv) changes in metal metabolism, v) vascular processes, and vi) neurotrophic deficiency. Very recently, neuroinflammation has been discussed as a facet of PDN. The development of novel therapeutic strategies is warranted to better understand PDN patomechanisms.
The present issue deals with new treatment options for damaged peripheral nerves in pre-diabetic and diabetic patients and in animal models of obesity and diabetes. Moreover, the inflammatory mechanism means that a re-examination of human and experimental PDN is warranted.
Dr. Joanna Kosacka
Dr. Marcin Nowicki
Dr. Petra Baum
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- peripheral diabetic neuropathy (PDN)
- pathogenetic factors
- therapeutic approaches
- oxidative stress